Canakinumab, an anti-IL-1β monoclonal antibody, has been approved for the treatment of FCAS, MWS, CAPS, sJIA, familial Mediterranean fever (FMF), mevalonate kinase deficiency (MKD), TNF receptor-associated periodic syndrome (TRAPS), and AOSD.677 A phase II clinical trial (NCT03775109) is exploring the potential benefits of canakinumab for the treatment of alcoholic hepatitis. The gene discussed is IL1B; the disease is Muckle-Wells syndrome.